A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Duvortuxizumab, A Humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Subjects With Relapsed or Refractory B-cell Malignancies

Trial Profile

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Duvortuxizumab, A Humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Subjects With Relapsed or Refractory B-cell Malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Duvortuxizumab (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 31 Aug 2017 According to the MacroGenics media release, the company announced that Janssen is terminating the collaboration and license agreement with MacroGenics due to treatment-related neurotoxicity relating to duvortuxizumab.
    • 31 Aug 2017 Status changed from recruiting to discontinued as per the MacroGenics media release.
    • 21 Apr 2017 Planned number of patients changed from 221 to 220.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top